Outlook Therapeutics’ eye disease drug has failed to match Roche’s Lucentis in a key trial. The biotech brushed off the ...

Proliferative vitreoretinopathy (PVR) is an eye condition that leads to blindness and can currently only be addressed with ...

The biotech is focused on signing on the dotted line before the end of the year, said CEO André Muller, who explained that ...

Despite winning an FDA green light nearly three months ago for its first wearable insulin delivery system, Embecta is now ...

On the heels Kronos Bio’s decision to can its last remaining clinical asset earlier this month, the company said it would ...

Neuralink said it has received a green light for a new clinical study to test the feasibility of connecting its ...

Trump previously selected Robert Francis Kennedy Jr. to head up the Department of Health and Human Services—the NIH’s parent ...

The academic-led, industry-partnered collaboration Equitable Breakthroughs in Medicine Development (EQBMED) has released an ...

Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...

A federal court jury has sided with Guardant Health, which had claimed that rival cancer test developer Natera went too far ...

Medigene will slim its head count by 40% and pause plans to get its first asset into the clinic in order to channel cash to ...

Alector’s AbbVie-partnered Alzheimer's disease asset has failed to slow disease progression in a phase 2 study, the latest in ...